Ozarks Regional Community Clinical Oncology Program (CCOP) is a consortium of two hospitals -- St. John's Regional Health Center and Lester E. Cox Medical Centers. There are twenty- three physicians willing to put patients on protocol. Groundwork in protocol management has been laid by five of the medical oncologists whose experience during the past five years has exposed them to a wide variety of NCI approved protocols. Centralizing data management offers these physicians the support necessary to generate a larger number of protocol studies. Quality assurance procedure and poly compliance is of the highest priority in implementing accurate and timely data submission. The Ozarks Regional CCOP serves a catchment area of 16 counties with a projected population of 600,000. Of the cancer patient population identified, 76% of the patients are 60 years of age and older. Since a steady increase in the elderly population is expected and since many are on fixed incomes, they are essentially under served in securing the benefits of therapeutic research protocols. To access centers where these protocols are available, residents must travel to distant major medical communities, e.g., Tulsa, 185 miles; Kansas City, 195 miles; St. Louis, 215 miles; and Little Rock 223 miles. Previous protocol experience has demonstrated the ability of the physicians to realize the projected 95.2 credits for therapeutic protocols and 49.1 credits for cancer control protocols for the first year. Subsequent cancer control yearly requirements of 30 credits and 50 credits can be easily attained. Ozarks Regional CCOP has come into being to expand the capability of the physician to reach more cancer patients with the benefits of research protocols. It seeks to work with its research base, SWOG and M.D. Anderson, and the NCI to reduce cancer morbidity and mortality so that the goal set forth for the year 2000 can be achieved.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA045560-01
Application #
3558679
Study Section
(SRC)
Project Start
1987-08-15
Project End
1990-05-31
Budget Start
1987-08-15
Budget End
1988-05-31
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
St. John's Regional Health Center
Department
Type
DUNS #
City
Springfield
State
MO
Country
United States
Zip Code
65804
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Ahmed, Amina; Deng, Wei; Tew, William et al. (2018) Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 150:300-305
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 157 publications